One-year atorvastatin treatment in hypercholesterolemic patients with or without carotid artery disease

International Angiology

Volumn 25, Issue 1, 2006, Pages 26-34

  Avellone, Gino ^a,b   Di Garbo, V ^a   Abruzzese, G ^a   Campisi, D ^a   De Simone, R ^a   Raneli, G ^a   Licata, G ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b NONE   (Italy)

Author keywords

Atorvastatin; Carotid artery; Fibrinogen; Heterozygous familial hypercholesterolemia; hs CRP

Indexed keywords

ACETYLSALICYLIC ACID; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; C REACTIVE PROTEIN; CHOLESTEROL; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTERY INTIMA PROLIFERATION; ARTICLE; B SCAN; CAROTID ARTERY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HEMATOCRIT; HUMAN; LIPID BLOOD LEVEL; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; TREATMENT OUTCOME;

EID: 33645798653     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Brown MS, Goldstein JL. A receptor mediated pathway for cholesterol homeostasis. Science 1986;232:34-47.
2. Hobbs HH, Brown MS, Goldstein JL. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum Mutat 1992;1:445-66.
3. The Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
4. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW et al. for the West of Scotland Coronary prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
5. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M et al. for ASCOT. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOTT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58.
6. Wilkinson B, Cockcroft JR. Cholesterol, endothelial function and cardiovascular disease. Curr Opin Lipidol 1998;9:237-42.
7. Rosenson RS., Tangney CC. Antiatherotrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998;279:643-50.
8. Gilligan DM, Sack MN, Casino PR, Quyyumi AA, Rasder DJ. Effect of antioxidant vitamins on low density lipoprotein oxidation and impaired endothelium-dependent vasodilation in patients with hypercholesterolemia. J Am Coll Cardiol 1994;24:1611-7.
9. Bellosta S, Bernini F, Ferri N, Quarato P, Canavesi M, Arnaboldi L. Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis 1998;137:S101-9.
10. Avellone G, Di Garbo V, Cordova R, Abruzzese G, Rotolo G, Raneli G et al. Activation of coagulation but normal fibrinolysis in patients with type IIa hyperlipoproteinemia. Thromb Res 1996;81:277-82.
11. Blaww G, Lagaay A, Smelt A, Westerndrop R. Stroke, statins and cholesterol: a meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-Coa reductase inhibitors. Stroke 1997;28;946-50.
12. Spurk P, Angelkort B, Selter P. Incidence of arteriosclerotic lesions of carotid arteries in chronic peripheral arterial disease and myocardial infarction. Angiology 1989;40:39-44.
13. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr for the Cardiovascular Health Study Collaborative Research Group Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med 1999;340: 14-22.
14. Cortellaro M, Cofrancesco E, Arbustini E, Rossi F, Negri A, Tremoli E et al. Atorvastatin and thrombogenicity of the carotid atherosclerotic plaque: the ATROCAP study. Thromb Haemost 2002;88:41-7.
15. Chambless LE, Heiss G, Folsom AR, Rosamond W, Szklo M, Sharrett AR et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Cornmunities (ARIC) Study, 1987-1993. Am J Epidemiol 1997;146:483-94.
16. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJP, Stalenhoef AFH. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomized, double-blind trial. Lancet 2001;357:577-81.
17. Pedersen TR, Faergeman O, Holme I, Olsson AG, Tikkanen MJ. Effect of greater LDL-C reduction on prognosis: the Incremental Decrease in Endpoints through Aggressive Lipid Lowering (IDEAL) trial. Atherosclerosis 1999;144 Suppl 1:38.
18. Lacoste L, Lam JYT, Hung J, Letchacovski G, Solymoss CB, Waters D. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995;92:3172-7.
19. Muscari A, Bozzoli C, Puddu GM, Sangiorgi Z, Dormi A, Rovinetti C et al. Association of serum C3 levels with the risk of myocardial infarction. Am J Med 1995;98:357-64.
20. Mollow KJ, Thompson MM, Schwalbe EC, Bell PR, Naylor AR, Loftus IM. Comparison of levels of matrix metalloproteinases, tissue inhibitor of metalloproteinase, interleukins, and tissue necrosis factor in carotid endarterectomy specimens from patient on versus not on statins preoperatively. Am J Cardiol 2004;94:144-6.
21. Mendall MA, Strachan DP, Butland BK, Ballam L, Morris J, Sweetnam PM et al. C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur Heart J 2000;21:1584-90.
22. Patrono C, Coller B, Dalen JE, FitzGerald GA, Fuster V, Gent M et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 2001;1l9(1 Suppl):39S-63S.
23. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients - Antithrombotic Trialists'(ATT) Collaboration. Br Med J 2002;324:71-86.
24. Patrono C. Efficacy and safety of aspirin in long-term management of atherotrombosis. Haernatologica 2002;87:6-8.
25. Nenci GG, Goracci S. Antithrombotic drugs for the secondary prevention of ischemic stroke. Ann Ital Med Int 2000;15:282-90.
26. Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation 1986;74:1399-403.
27. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of the low- density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
28. Ridker PM. High-sensitivity C-reactive protein. Potential adjunct for global risk assessement in primary prevention of cardiovascular disease. Circulation 2001;103:1813-8.
29. Pedersen TR, Faergeman O, Holme I, Olsson AG, Tikkanen MJ. Effect of greater LDL-C reduction on prognosis: the Incremental Decrease in Endpoints throuch Aggressive Lipid Lowering (IDEAL) trial. Atherosclerosis 1999;144 Suppl 1:38.
30. Dallongeville J, Fruchart JC, Maigret P, Bertolini S, Bittolo Bon G, Campbell MM et al. Double-blind comparison of apolipoprotein and lipoprotein particle lowering effects of atorvastatin and pravastatin monotherapy in patients with primary hypercholesterolemia. J Cardiovasc Pharmacol Therapeut 1998;3:103-10.
31. Jones P, Kafonek S, Laurora I, Hunninghake D, for the CURVES investigators. Comparative dose efficacy study of atorvastatin versus sinvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998;81:582-7.
32. Executive Summary of The Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
33. Koren MJ, Hunninghake DB; ALLIANCE Investigators. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study. J Am Coll Cardiol 2004;44:1772-9.
34. Athyros VG, Mikhailidis DP, Papageorgiou AA, Symeonidis AN, Daskalopoulou SS, Kakafika AI et al.; GREACE Study Collaborative Group. Relationship between LDL-C and non-HDL-C levels and clinical outcome in the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr Med Res Opin 2004;20:1385-92.
35. Bertolini S, Bittolo Bon G, Campbell LM, Farnier M, Langan J, Mahla G et al. Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. Atherosclerosis 1997;130:191-7.
36. Bard JM, Dallongeville J, Hagen E, Pfister P, Ose L, Fruchart JC et al. Comparison of the effect of fluvastatin, on hydroxymethyl glutaryl coenzyme A reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by apolipoprotein composition. Metabolism 1995;44:1447-54.
37. Seifert S, Kazatchkine MD. The complement system and atherosclerosis. Atherosclerosis 1988;73:91-104.
38. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999;340:115-26.
39. Strano A, Davì G, Novo S, Avellone G. Thrombophilic states and atherosclerosis. In: Crepaldi G, Fellin R, Olsson AG, Toffano G, editors. Arteriosclerosis brain disease. New York: Raven Press; 1983.p. 173-80.
40. Wilhelmsen L, Svärdsudd K, Korsan-Bengtsen K, Larson B, Welin L, Tibblin G. Fibrinogen as risk factor for stroke and myocardial infarction. N Engl J Med 1984;311: 501-5.
41. Heinrich J, Balleisen L, Shulte H, Assman G, Van De Loo J. Fibrinogen and factor VII in the prediction of coronary risk: results from the PROCAM study in healthy men. Arterioscler Thromb Vasc Biol 1994; 14:54-9.
42. Cortellaro M, Boschetti C, Cofrancesco E, Zanussi C, Catalano M, De Gaetano G et al. The PLAT study: Hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients. Principal results. Arterioscler Thromb Vasc Biol 1992; 12:1063-70.
43. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factor and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993;342:1076-9.
44. Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996; 144:537-47.
45. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999;99:237-42.
46. Mader SR, Chenoweth DE, Goldstein M, Perez HD. Chemotactic responses of human peripheral blood monocytes to the complement-derived peptides C5a and C5a desArg. J Immunol 1985;134:3325-31.
47. Gilligan DM, Guetta V, Panza JA, Garcia CE, Quyyumi AA, Cannon III RO. Selective loss of microvascular endothelial function in human hypercholesterolemia. Circulation 1994;90:35-41.
48. Neri Serneri GG. Coronary thrombosis: plaque rupture or acute infiammatory reaction? In: Neri Serneri GG, Gensini GF, Abbate R, Prisco D, editors. Atherosclerosis infiammation and thrombosis. Florence, Italy: Scientific Press; 1993.p. 185-200.
49. Pasceri V, Willerson JT, Yeh ETH. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000;102:2165-8.
50. Gaspardone A, Versaci F, Proietti I, Tomai F, Altamura L, Skossyreva O et al. Effect of Atorvastatin (80 mg) initiated at the time of coronary artery stent implantation on C-reactive protein and six-month clinical events. Am J Cardiol 2002;90:786-9.
51. Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S. Effect of hydroxymetil glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001;103:1933-5.
52. Undas A, Brummel K, Musial J, Mann KG, Szczeklik A. Sinvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor V inactivation. Circulation 2001;103: 2248-53.
53. Avellone G, Di Garbo V, Cordova R, Raneli G, De Simone R, Bompiani GD. Changes induced by pravastatin on hemostatic and fibrinolytic pattern in patients with type IIb hyperlipoproteinemia. Curr Ther Res 1994;55:1335-44.
54. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-43.
55. Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu C-R, Liu C-H et al. The role of carotid arterial intima-media thickness in predicting clinicall coronary events. Ann Intern Med 1998;128:262-9.
56. Levine GN, Keaney JF, Vota JA. Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. N Engl J Med 1995;332:512-21.
57. Kent SM, Taylor AJ. Usefulness of lowering low-density lipoprotein cholesterol to <70 mg/dl and usefulness of C-reactive protein in patient selection. Am J Cardiol 2003;92: 1224-7.